Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
SOPH · Nasdaq · United States · Services-Computer Processing & Data Preparation
In shortSOPHiA GENETICS SA is loss-making, burns cash and holds more cash than debt, with revenue growing (+18.6% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -91.8% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -102.2% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -110.0% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -59.0% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.96× | 97/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.01× | 55/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -15.57× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -10.93 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -47.2% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 14.5% | 58/100 |
| Operating margin volatility | 43.0% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 17.6% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
2 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 40 | 48 | 62 | 65 | 77 |
| Cost of revenue | 15 | 16 | 19 | 21 | 25 |
| Gross profit | 25 | 31 | 43 | 44 | 52 |
| Research & development | 27 | 35 | 37 | 34 | 34 |
| Operating income | (71) | (88) | (75) | (67) | (71) |
| Interest expense | 0.7 | 0.6 | 0.6 | 1.9 | 4.6 |
| Pre-tax income | (74) | (88) | (78) | (61) | (77) |
| Income tax | 0.2 | (0.1) | 0.5 | 1.2 | 1.5 |
| Net income | (74) | (87) | (79) | (62) | (79) |
| Diluted EPS | −$1.33 | −$1.36 | −$1.22 | −$0.95 | −$1.17 |
| Diluted shares (millions) | 55 | 64 | 65 | 66 | 68 |
2 older years available with the 10-year history. Essential plan, from €8.25/month →
−10.93 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
2/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Mar 3, 2026